Claims for Patent: 5,693,616

Summary for Patent: 5,693,616

Title:	Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
Abstract:	Synthetic polypeptide analogs of parathyroid hormone PTH, parathyroid hormone related peptide PTHrp, and of the physiologically active truncated homologs and analogs of PTH and PTHrp, in which amino acid residues (22-31) form an amphipathic .alpha.-helix, said residues (22-31) selected from hydrophilic amino acids (Haa) and lipophilic amino acids (Laa) ordered in the sequence: Haa (Laa Laa Haa Haa).sub.2 Laa and their pharmaceutically acceptable salts are useful for the prophylaxis and treatment of osteoporosis in mammals. Processes for the production of the polypeptides via solid phase and recombinant methods are provided.
Inventor(s):	Krstenansky; John L. (Palo Alto, CA), Nestor, Jr.; John J. (Cupertino, CA), Vickery; Brian H. (Mountain View, CA)
Assignee:	Syntex (U.S.A.) Inc. (Palo Alto, CA)
Application Number:	08/443,863
Patent Claims:	1. A method for treating mammalian conditions characterized by decreases in bone mass, which method comprises administering to a subject in need thereof an effective bone mass increasing amount of a modified parathyroid hormone related polypeptide (PTHrP) of the formula: Ala Val Ser Glu Xaa.sup.5 Gln Leu Leu His Asp Xaa.sup.11 Gly Xaa.sup.13 Ser Ile Gln Asp Leu Xaa.sup.19 Arg Xaa.sup.21 Xaa.sup.22-31 Xaa.sup.32 Xaa.sup.33 Xaa.sup.34 Term, wherein: Xaa.sup.5 is His or Ala; Xaa.sup.11 and Xaa.sup.13 are independently Lys, Arg, or Leu; Xaa.sup.19 and Xaa.sup.21 are independently Ala or Arg; Xaa.sup.22-31 is selected from the group consisting of (SEQ ID NOS: 26, 27, 28, 29, and 30); Xaa.sup.32 is His or Lys; Xaa.sup.33 is Thr, Glu, or Ala; Xaa.sup.34 is Ala, hSer, Tyr, or Leu; and Term is OH, NR.sub.2, lactone, or Gly Arg Arg, where R is H or (C.sub.1 -C.sub.4) alkyl; and the pharmaceutically acceptable salts thereof. 2. A method of claim 1 in which the condition to be treated is osteoporosis. 3. A method of claim 1 in which the effective amount of polypeptide for increasing bone mass is from about 0.01 .mu.g/kg/day to about 1 .mu.g/kg/day. 4. A method of claim 1 comprising administration of a polypeptide having an amino acid sequence as set forth in (SEQ ID NO:5). 5. A method of claim 1 comprising administration of a polypeptide having an amino acid sequence as set forth in (SEQ ID NO:6). 6. A method of claim 1 comprising administration of a polypeptide having an amino acid sequence as set forth in (SEQ ID NO:7). 7. A method of claim 1 comprising administration of a polypeptide having an amino acid sequence as set forth in (SEQ ID NO:8). 8. A method of claim 1 comprising administration of a polypeptide having an amino acid sequence as set forth in (SEQ ID NO:9). 9. A method of claim 1 comprising administration of a polypeptide having an amino acid sequence as set forth in (SEQ ID NO:10). 10. A method of claim 1 comprising administration of a polypeptide having an amino acid sequence as set forth in (SEQ ID NO:11). 11. A method of claim 1 comprising administration of a polypeptide having an amino acid sequence as set forth in (SEQ ID NO:12). 12. A method of claim 1 comprising administration of a polypeptide having an amino acid sequence as set forth in (SEQ ID NO:13). 13. A method of claim 1 comprising administration of a polypeptide having an amino acid sequence as set forth in (SEQ ID NO:14). 14. A method of claim 1 comprising administration of a polypeptide having an amino acid sequence as set forth in (SEQ ID NO:15). 15. A method of claim 1 comprising administration of a polypeptide having an amino acid sequence as set forth in (SEQ ID NO:16). 16. A method of claim 1 comprising administration of a polypeptide having an amino acid sequence as set forth in (SEQ ID NO:17). 17. A method of claim 1 comprising administration of a polypeptide having an amino acid sequence as set forth in (SEQ ID NO:18). 18. A method of claim 1 comprising administration of a polypeptide having an amino acid sequence as set forth in (SEQ ID NO:19). 19. A method of claim 1 comprising administration of a polypeptide having an amino acid sequence as set forth in (SEQ ID NO:20). 20. A method of claim 1 comprising administration of a polypeptide having an amino acid sequence as set forth in (SEQ ID NO:21). 21. A method of claim 1 comprising administration of a polypeptide having an amino acid sequence as set forth in (SEQ ID NO:22). 22. A method for treating mammalian conditions characterized by decreases in bone mass, which method comprises administering to a subject in need thereof an effective bone mass increasing amount of a modified parathyroid hormone (PTH) polypeptide of the formula: Xaa.sup.1 Val Ser Glu Ile Gln Xaa.sup.7 Xaa.sup.8 His Asn Leu Gly Lys His Leu Xaa.sup.16 Ser Xaa.sup.18 Xaa.sup.19 Arg Xaa.sup.21 Xaa.sup.22-31 His Asn Xaa.sup.34 Term, wherein: Xaa.sup.1 is Ser or Ala; Xaa.sup.7 is Leu or Phe; Xaa.sup.8 is Met or Nle; Xaa.sup.16 is Asn or Ser; Xaa.sup.18 is Leu, Met, or Nle; Xaa.sup.19 is Glu or Arg; Xaa.sup.21 is Val or Arg; Xaa.sup.22-31 is selected from the group consisting of (SEQ ID NOS: 26, 27, 28, 29, and 30); Xaa.sup.34 is Phe or Tyr; Term is OH or NR.sub.2, where R is H or a (C.sub.1 -C.sub.4) alkyl; and the pharmaceutically acceptable salts thereof. 23. A method of claim 22 in which the condition to be treated is osteoporosis. 24. A method of claim 22 in which the effective amount of polypeptide for increasing bone mass is from about 0.01 .mu.g/kg/day to about 1.0 .mu.g/kg/day. 25. A method of claim 22 comprising administration of a polypeptide having an amino acid sequence as set forth in (SEQ ID NO:23). 26. A method of claim 22 comprising administration of a polypeptide having an amino acid sequence as set forth in (SEQ ID NO:24). 27. A method for treating mammalian conditions characterized by decreases in bone mass, which method comprises administering to a subject in need thereof an effective bone mass increasing amount of a modified parathyroid hormone related polypeptide (PTHrP) selected from the group consisting of SEQ ID NOS: 7, 8, and 9.

Details for Patent 5,693,616

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2014-12-02